Skip to main content
. 2024 Jul 22;41(9):3569–3584. doi: 10.1007/s12325-024-02938-2

Fig. 2.

Fig. 2

Barriers to the use of GLP-1 RAs: percentage of agreement (6–7 agree) by subgroup. CV cardiovascular, CVD cardiovascular disease, GLP-1 RAs glucagon-like peptide 1 receptor agonists, N number of physicians